Is NVO or OCUL more undervalued in 2026?

CirclFi compares Novo Nordisk A/S (NVO) and Ocular Therapeutix, Inc. (OCUL) using 13 institutional-grade valuation models. NVO has a Quality of Company score of 10.0/10 while OCUL scores 7.2/10.

Which is a better buy — NVO or OCUL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NVO and OCUL valuations compare?

NVO at $45.58 and OCUL at $9.01 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NVO vs OCUL Valuation Comparison 2026 — Intrinsic Value Analysis

NVO

Pharmaceutical Preparations

Novo Nordisk A/S

Quality

10.0

out of 10

Value Trap

SAFE

Price

$45.58

Last close

Models

12/13

Active

OCUL

Pharmaceutical Preparations

Ocular Therapeutix, Inc.

Quality

7.2

out of 10

Value Trap

SAFE

Price

$9.01

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	NVO Fair Value	NVO Upside	OCUL Fair Value	OCUL Upside
Bayesian DCF	Intrinsic	$31.49	-30.9%	$3.69	-59.0%
Earnings Power Value	Intrinsic	$44.06	-3.3%	$2.78	-70.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NVO vs OCUL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NVO vs OCUL — Which Stock Is More Undervalued?

NVO scores higher with a 10.0/10 quality rating vs OCUL's 7.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Novo Nordisk A/S (NVO) and Ocular Therapeutix, Inc. (OCUL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NVO currently trades at $45.58 with a QOC of 10.0/10, while OCUL trades at $9.01 with a QOC of 7.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).